Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Infants with congenital heart defects have reduced brain volumes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The risk of developing a meningioma during and after pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. High-intensity leg cycling alters the molecular response to resistance exercise in the arm muscles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

There is a large unmet need for a prophylactic hepatitis C virus (HCV) vaccine to control the ongoing epidemic with this deadly pathogen. Many antiviral vaccines employ whole viruses as antigens. For HCV, this approach became feasible following the development of infectious cell culture systems for virus production. However, the lack of efficient downstream processes (DSP) for HCV purification poses a roadblock for the development of a whole virus vaccine. Using cell culture-derived genotype 1a HCV we developed a scalable and efficient DSP train, employing commonly used clarification and ultrafiltration techniques, followed by two membrane-based chromatography steps. For virus capture, steric exclusion chromatography using cellulose membranes was established, resulting in a virtually complete virus recovery with > 99% protein and 84% DNA depletion. Virus polishing was achieved by sulphated cellulose membrane adsorbers with ~ 50% virus recovery and > 99% protein and 90% DNA depletion. Additional nuclease digestion resulted in 99% overall DNA depletion with final DNA concentrations of 2 ng/mL. Process results were comparable for cell culture-derived HCV of another major genotype (5a). This study provides proof-of-concept for establishment of an efficient and economically attractive DSP with potential application for production of an inactivated whole virus vaccine against HCV for human use.

OriginalsprogEngelsk
Artikelnummer16261
TidsskriftScientific Reports
Vol/bind10
Udgave nummer1
Sider (fra-til)16261
ISSN2045-2322
DOI
StatusUdgivet - 1 okt. 2020

ID: 60979076